In Vitro Activities of the New Antifungal Drug Eberconazole and Three Other Topical Agents against 200 Strains of Dermatophytes

Journal of Clinical Microbiology

Volumn 41, Issue 11, 2003, Pages 5209-5211

  Fernández Torres, Belkys ^a   Inza, Isabel ^a   Guarro, Josep ^a,b  

^a FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

^b UNIVERSITAT ROVIRA I VIRGILI   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CLOTRIMAZOLE; EBERCONAZOLE; KETOCONAZOLE; MICONAZOLE;

ANIMAL CELL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DERMATOMYCOSIS; DERMATOPHYTE; DILUTION; DRUG ACTIVITY; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; INCUBATION TIME; MICRODILUTION METHOD; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SPECIES IDENTIFICATION; STRAIN DIFFERENCE; TEMPERATURE MEASUREMENT;

ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; ARTHRODERMATACEAE; CLOTRIMAZOLE; HUMANS; KETOCONAZOLE; MICONAZOLE; MICROBIAL SENSITIVITY TESTS; SPECIES SPECIFICITY;

ANIMALIA; ARTHRODERMATACEAE;

EID: 10744231471     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.41.11.5209-5211.2003     Document Type: Article

References (20)

1. Albanese, G., R. Di Cintio, P. Giorgetti, G. Galviati, and M. Ciampini. 1992. Recurrent tinea pedis: a double blind study on the prophylactic use of fenticonazole powder. Mycoses 35:157-159.
2. Alou Cervera, L., J. R. Maestre, R. Moreno, and Grupo para el estudio del consumo de antimicrobianos en España. 2001. Consumo de antifúngicos de uso tópico en España. Rev. Esp. Quimioter. 14:340-344.
3. Bonifaz, A., and A. Saul. 2000. Comparative study between terbináfine 1% emulsion-gel versus ketoconazole 2% cream in tinea cruris and tinea corporis. Eur. J. Dermatol. 10:107-109.
4. Del Palacio, A., F. J. Ortiz, A. Pérez, C. Pazos, M. Garau, and E. Font. 2001. A double-blind randomized comparative trial: eberconazole 1% cream versus clotrimazole 1% cream twice daily in Candida and dermatophyte skin infections. Mycoses 44:173-180.
5. Del Palacio, A., S. Cuétara, and A. Rodríguez. 1995. Topical treatment of tinea corporis and tinea cruris with eberconazole (WAS 2160) cream 1% and 2%: a phase II dose-finding pilot study. Mycoses 38:317-324.
6. Fernández-Torres, B., A. J. Carrillo, E. Martín, A. del Palacio, M. K. Moore, A. Valverde, M. Serrano, and J. Guarro. 2001. In vitro activities of 10 antifungal drugs against 508 dermatophyte strains. Antimicrob. Agents Chemother. 45:2524-2528.
7. Fernández-Torres, B., F. J. Cabañes, A. Carrillo-Muñ oz, A. Esteban, I. Inza, L. Abarca, and J. Guarro. 2002. Collaborative evaluation of optimal antifungal susceptibility testing conditions for dermatophytes. J. Clin. Microbiol. 40:3999-4003.
8. Fernández-Torres, B., M. Pereiro, and J. Guarro. 2002. Comparison of two methods for antifungal susceptibility testing of Trichophyton rubrum. Eur. J. Clin. Microbiol. Infect. Dis. 21:70-71.
9. Font, E., J. Freixes, and J. Julve. 1995. Perfil del nuevo antimicótico tópico eberconazol. Rev. Iberoam. Micol. 12:16-17.
10. Hull, P. R. 1997. Onychomycosis-treatment, relapse and re-infection. Dermatology 194:7-9.
11. Macura, A. 1993. In vitro susceptibility of dermatophytes to antifungal drugs: a comparison of two methods. Int. J. Dermatol. 32:533-536.
12. McClellan, K. J., L. R. Wiseman, and A. Markham. 1999. Terbinafine. An update of its use in superficial mycoses. Drugs 58:179-202.
13. Niewerth, M., and H. C. Korting. 2000. The use of systemic antimycotics in dermatotherapy. Eur. J. Dermatol. 10:155-160.
14. Pujol, I., J. Capilla, B. Fernández-Torres, M. Ortoneda, and J. Guarro. 2002. Use of the sensititre colorimetric microdilution panel for antifungal susceptibility testing of dermatophytes. J. Clin. Microbiol. 40:2618-2621.
15. Rubin, A. I., B. Bagheri, and R. K. Scher. 2002. Six novel antimycotics. Am. J. Clin. Dermatol. 3:71-81.
16. Schopf, R., O. Hettler, M. Bräutigam, G. Weidinger, U. Kaben, P. Mayser, and V. Resl. 1999. Efficacy and tolerability of terbinafine 1% topical solution used for 1 week compared with 4 weeks clotrimazole 1% topical solution in the treatment of interdigital tinea pedis: a randomized, double-blind, multicentre, 8-week clinical trial. Mycoses 42:415-420.
17. Suschka, S., B. Fladung, and H. F. Merk. 2002. Clinical comparison of the efficacy and tolerability of once daily canesten with twice daily nizoral (clotrimazole 1% cream vs. ketoconazole 2% cream) during a 28-day topical treatment of interdigital tinea pedis. Mycoses 45:91-96.
18. Torres-Rodríguez, J. M., N. Madrenys-Brunet, and L. Montsant. 1999. Tratamiento tópico de la candidosis cutánea experimental del cobayo con eberconazol. Rev. Iberoam. Micol. 16:43-45.
19. Torres-Rodríguez, J. M., R. Mendez, O. López-Jodra, Y. Morera, M. Espasa, T. Jimenez, and C. Lagunas. 1999. In vitro susceptibilities of clinical yeast isolates to the new antifungal eberconazole compared with their susceptibilities to clotrimazole and ketoconazole. Antimicrob. Agents Chemother. 43:1258-1259.
20. Walsh, T. J., and A. H. Groll. 1999. Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transplant. Infect. Dis. 1:247-241.